Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

Part of paid clinical trials in Lebanon, New Hampshire.

Sponsor
Tyler J Curiel
Study ID
NCT06815497
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Telmisartan — DRUG
    Telmisartan will be introduced as a 40 mg tablet to be taken orally once daily. In participants not experiencing telmisartan dose limiting toxicity, the dose will be escalated to a maximum of 80 mg

Study Details

The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.

Key Dates

Start date
Jan 21, 2026
Status verified
Jan 2026
Primary completion
Apr 14, 2027
Completion
May 14, 2029

Study Design

Enrollment
33 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Telmisartan with Standard of Care Treatment
    oral telmisartan in combination with standard of care chemotherapy. chemotherapy regimen is preferably doxorubicin (preferably liposomal doxorubicin) but paclitaxel, nab-paclitaxel, or docetaxel are allowed per investigator or patient preference

Primary Outcome Measure

Progression free survival [ Time Frame: 48 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Dartmouth HitchcockLebanonNew Hampshire03756
Ivy Wilkinson-Ryan, MD
Ivy Wilkinson-Ryan, MD (PRINCIPAL_INVESTIGATOR)
Dartmouth-Hitchcock ManchesterManchesterNew Hampshire03104
Ivy Wilkinson-Ryan, MD
[email protected]
603-650-5000
Ivy Wilkinson-Ryan, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Lebanon, NH

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Dartmouth Hitchcock· Lebanon, NHDartmouth-Hitchcock Manchester· Manchester, NH

Related Studies